Visit measurecme.org

EARN UP TO 3 AMA PRA Category 1 Credits


The sixth edition of the MEASUREme™ Resource Module is a comprehensive educational resource for psychiatrists and other health care providers involved in the diagnosis, treatment, and management of bipolar disorder.

The MEASUREme™ mission is to provide physicians with a comprehensive continuing medical education program that reflects evolving treatment strategies in psychiatric disorders while addressing educational objectives critical to disease management.

This educational activity is sponsored by The France Foundation and is supported by an educational grant from AstraZeneca.

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Please review the following CME information before beginning this activity:

NEEDS STATEMENT/TARGET AUDIENCE
Despite advances in bipolar disorder research and patient care practices, diagnosis is often delayed or mistaken, and many people who could benefit are not receiving the most effective medical management. Even for patients with accurate diagnosis and therapeutic regimens, there are obstacles to achieving positive therapeutic outcomes due to multiple challenges. As such, this activity has been planned in accordance with the need to provide psychiatrists and other health care providers the resources and practical tools to address the spectrum of issues in the management of bipolar disorder and its comorbidities, and to individualize care using evidence-based approaches.

EDUCATIONAL ACTIVITY OBJECTIVES
Upon completion of this activity, the participants should be able to:
  • Describe neurophysiological findings and neurocognitive deficits in bipolar disorder and various phases of the illness
  • Discuss how individual factors such as age, the presence of comorbidities, or ethnic/cultural issues impact the diagnosis and treatment of bipolar disorder
  • Interpret emerging data from studies on bipolar disorder therapy
  • Determine the appropriate strategies for multimodal combination therapies in the acute and long-term management of bipolar disorder
ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT STATEMENT
The France Foundation designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

RELEASE/EXPIRATION DATES
This activity is eligible for CME credit from June 2008 through June 30, 2009.

DISCLAIMER
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and AstraZeneca assume no liability for the information herein.

EDUCATIONAL REVIEW BOARD

BOARD CO-CHAIRS
Henry A. Nasrallah, MD
Board Co-Chair
Professor of Psychiatry, Neurology,
and Neuroscience

University of Cincinnati
College of Medicine
Cincinnati, Ohio


Peter F. Buckley, MD
Board Co-Chair
Professor and Chairman
Department of Psychiatry
Medical College of Georgia
Augusta, Georgia


BOARD MEMBERS
Michael H. Allen, MD
Associate Professor of Psychiatry
Director, Emergency and Consultation Psychiatry
Co-Director, Mood Disorders Program
University of Colorado
Health Sciences Center
Denver, Colorado

Claudia F. Baldassano, MD
Assistant Professor of Psychiatry
Staff Psychiatrist
Director, Bipolar Outpatient Clinic
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Joseph R. Calabrese, MD
Co-Director, NIMH-funded
Bipolar Disorders Research Center
Director, Mood Disorders Program
University Hospitals of Cleveland
Professor of Psychiatry
Case Western Reserve University
School of Medicine
Cleveland, Ohio

Andrew J. Cutler, MD
Courtesy Assistant Professor
Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Florida

Melissa P. DelBello, MD
Associate Professor of Psychiatry and Pediatrics
Co-Director, Bipolar and Psychotic Disorders
Research Program
Director, Child and Adolescent Psychiatry Division, Psychotic and Bipolar Disorder Research Program
University of Cincinnati
College of Medicine
Co-Director, Mood Disorders Program
Children's Hospital Medical Center
Cincinnati, Ohio
Joseph F. Goldberg, MD
Clinical Associate Professor of Psychiatry
Mount Sinai School of Medicine
New York, New York
Director, Affective Disorders Program
Silver Hill Hospital
New Canaan, Connecticut

Roger S. McIntyre, MD, FRCPC
Associate Professor of Psychiatry and Pharmacology
University of Toronto
Head of the Mood Disorders
Psychopharmacology Unit

University Health Network
Toronto, Canada

Robert M. Post, MD
Professor of Psychiatry
Penn State College of Medicine
Hershey, Pennsylvania
Head, Bipolar Collaborative Network
Chevy Chase, Maryland

Gary S. Sachs, MD
Director, Bipolar Treatment Center
Director, Bipolar Mood Disorder Program
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School
Boston, Massachusetts

S. Charles Schulz, MD
Professor and Head of Psychiatry
University of Minnesota Medical School
Minneapolis, Minnesota

Stephen M. Strakowski, MD
Professor and Chairman
University of Cincinnati
College of Medicine
Cincinnati, Ohio

Alan C. Swann, MD
Pat R. Rutherford, Jr. Professor
Vice Chair for Research

Department of Psychiatry and Behavioral Sciences
The University of Texas Medical School and Graduate School of Biomedical Sciences
Houston, Texas

FACULTY DISCLOSURE
It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty participating in this activity will disclose to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a faculty member with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all faculty conflicts of interest prior to the release of this activity.

Michael H. Allen, MD, has served as consultant for Abbott Laboratories, Alexza Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, and Pfizer. He has received research funding and/or grant support from Abbott Laboratories, Alexza Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceutica, and Pfizer.

Claudia F. Baldassano, MD, has served as a consultant and on speakers bureaus for AstraZeneca, GlaxoSmithKline, and Pfizer.

Peter F. Buckley, MD, has served as a consultant for AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Janssen Pharmaceutica, Lundbeck, Pfizer, Solvay, and Wyeth. He has received honoraria from Bristol-Myers Squib, Janssen Pharmaceutica, Lundbeck, and Pfizer. Dr. Buckley has received grant and research support from AstraZeneca, National Institute of Mental Health, Pfizer, Solvay, and Wyeth.

Joseph R. Calabrese, MD, has served as a consultant for and has received honoraria from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Janssen Pharmaceutica, Johnson & Johnson, Solvay, and Wyeth. He has received research funding from Abbott Laboratories, AstraZeneca, The Cleveland Foundation, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharamceutica, NARSAD, Repligen, and Stanley Medical Research Institute.

Andrew J. Cutler, MD, has served as a consultant and as a speaker for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Otsuka Pharmaceutical, Pfizer, Sepracor, Shire, and Vanda Pharmaceuticals. He has received research grants from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Cephalon, Dainippon Sumitomo Pharma, Eli Lilly and Company, Forest Research Institute, GlaxoSmithKline, Janssen Pharmaceutica, JDS Pharmaceuticals, Johnson & Johnson, Memory Pharmaceuticals, Novartis, Organon, Otsuka Pharmaceutical, Pfizer, Sanofi, Sepracor, Shire, Solvay, Vanda Pharmaceuticals, and Wyeth. Dr. Cutler has served as a consultant for Supernus Pharmaceuticals.

Melissa P. DelBello, MD, has received grant and research support from AstraZeneca, Eli Lilly and Company, Janssen Pharmaceutica, Pfizer, Shire, and Somerset Pharmaceuticals. She has served as a consultant for AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, and Pfizer. She has received honoraria from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer.

Joseph F. Goldberg, MD, has served on speakers bureaus for Abbott Laboratories, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, and Pfizer. He has served as a consultant for Eli Lilly and Company and GlaxoSmithKline.

Roger S. McIntyre, MD, FRCPC, has served as a consultant for AstraZeneca, Biovail, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Organon, Pfizer, Shire, Solvay, and Wyeth. He has served on speakers bureaus for AstraZeneca, Biovail, Eli Lilly and Company, Janssen-Ortho, and Lundbeck. Dr. McIntyre also has received grant and research funding from Eli Lilly and Company, NARSAD, and Stanley Medical Research Institute.

Henry A. Nasrallah, MD, has served as a consultant for Abbott Laboratories, AstraZeneca, Janssen Pharmaceutica, Pfizer, and Vanda Pharmaceuticals. He has received honoraria from Abbott Laboratories, AstraZeneca, Janssen Pharmaceutica Products, and Pfizer. He has also received grant and research support from AstraZeneca, Janssen Pharmaceutica, Pfizer, and Sanofi.

Robert M. Post, MD, has served as a consultant for and received honoraria from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline.

Gary S. Sachs, MD, has served as a consultant for Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Cephalon, Elan, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Memory Pharmaceuticals, Merck, Novartis, Organon, Pfizer, Repligen, Sanofi, Shire, Sigma-Tau, Solvay, and Wyeth. He has received research support from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Memory Pharmaceuticals, NIMH, Novartis, Pfizer, Repligen, Shire, and Wyeth. Dr. Sachs has received honoraria from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceutica, Memory Pharmaceuticals, Novartis, Pfizer, Sanofi, and Wyeth. Dr. Sachs is a stockholder of Concordant Rater Systems.

S. Charles Schulz, MD, has received honoraria from AstraZeneca and Eli Lilly and Company. He has received grants from Abbott Laboratories, AstraZeneca, and Eli Lilly and Company. He has also served as a consultant for AstraZeneca, Eli Lilly and Company, and Vanda Pharmaceuticals.

Stephen M. Strakowski, MD, has served on speakers bureaus for DiMedix. He has received research support from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Forest Laboratories, Janssen Pharmaceutica, Martek Biosciences, Nutrition 21, Pfizer, and Repligen, and he has served as consultant for Eli Lilly and Company, Pfizer, and Tikvah Therapeutics.

Alan C. Swann, MD, has served as consultant for Abbott Laboratories, AstraZeneca, Pfizer, and Sanofi-aventis. Dr. Swann has served on speakers bureaus for Abbott Laboratories, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, Pfizer, and Sanofi-aventis. He has received research funding and grant support from PPD Development, and Pfizer.

ORGANIZATION OF THE RESOURCE MODULE
The MEASUREme™ Resource Module, which consists of PowerPoint® slides with speaker notes, should take approximately 3 hours to complete. The participant should complete the following, in the order listed below:

  • Read the objectives and other introductory information herein
  • View the material in the Resource Module online
  • Complete the CME Attestation/Evaluation
  • Complete the Posttest
  • Participants who complete the CME Attestation/Evaluation and Posttest will be issued a CME certificate within one month of submission to The France Foundation

The CME Attestation/Evaluation provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and his or her views on future educational needs. To receive credit for this activity, follow the instructions provided on the CME Attestation/Evaluation. CME credit will be valid through June 30, 2009.

You may also choose to use these slides as the sole source of information for a lecture, or combine them with slides from another source. The MEASUREme™ Resource Module is divided into 3 slide sections:

Slide Section 1: Neurobiology
Slide Section 2: Diagnostic Updates/Comorbidities
Slide Section 3: Principles of Disease Management

INSTRUCTIONS FOR OBTAINING CME CREDIT
Click here to open the CME Attestation/Evaluation and Posttest.

The form is offered in Adobe® Acrobat® (PDF) format. If needed, you can acquire the free software here » download Acrobat Reader®.

To receive CME credit, complete the CME Attestation/Evaluation and Posttest and fax or mail the completed forms to:

MEASUREme
The France Foundation
230 Shore Road
Old Lyme, Connecticut 06371
Toll Free: (866) 856-1998
Fax: (860) 434-5390
[email protected]

CONTACT INFORMATION
For further information or technical assistance, please contact a MEASUREme™ representative at the contact information above.


To access the educational components, please click on one of the following: